- Conditions
- Type 1 Diabetes, T1D Diabetic Chronic Kidney Disease, T1D Heart Failure, Cardio-renal Vascular Function and Failure
- Interventions
- Finerenone, Sotagliflozin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 2:47 AM EDT